



T H E R A P E U T I C S I N C

## COMPANY PROFILE

**Somnus Therapeutics, Inc.** (Bedminster, NJ) is a private drug development company formed by Care Capital LLC, which is developing an oral therapeutic to further address the major need of insomnia patients: preventing early awakening without next-day hangover.

### Insomnia Market Opportunity

Although insomnia is the most prevalent (up to 40% of the population) sleep disorder, only 20% of patients pursue pharmaceutical treatments, in part because available therapeutics do not meet most insomniacs' goals for sleep improvement. Somnus sees significant opportunity within the multi-billion dollar insomnia market for a new treatment that delivers improved satisfaction to patients and an improved risk/reward profile to investors. To those ends, the company has licensed from SkyePharma PLC (LSE: SKP) a new controlled-release formulation of a non-benzodiazepine hypnotic pharmaceutical (SKP-1041).

### Clinical Strategy

By leveraging the development of a chemical entity from the most successful class of current insomnia drugs using technical advances in formulation, controlled-release, and clinical testing, we believe we can speed development and reduce clinical costs to increase return on investment.

### Key Differentiators

- Multi-billion dollar insomnia market is vastly underpenetrated
- There is significant market opportunity for an insomnia therapeutic that improves on current "sleep maintenance" drugs
- Product addresses the top need of insomnia patients: taking a pill at bedtime avoids confusion and prevents early awakening with no next-day hangover
- Product is a novel formulation of a drug from the most successful class of insomnia drugs, licensed from SkyePharma and using GeoClock controlled-release technology
- Clinical strategy leverages advances in sleep research and clinical testing to speed development
- Company's virtual, single-product business model reduces costs and accelerates development
- Experienced drug development team with successful IND and NDA submissions

#### — MANAGEMENT TEAM —

Gary Cupit, PharmD - *Chief Executive Officer*  
 Mary Osbakken, MD, PhD - *Chief Medical Officer*  
 Christine Blumhardt, PharmD -  
*Chief Regulatory Officer*  
 Linda Hogan, MS, MBA - *Chief Business Officer*  
 Anne McCormick, MSW -  
*Director, Clinical Project Management*

#### — BOARD of DIRECTORS —

Gary Cupit, PharmD, *CEO Somnus Therapeutics*  
 Linda Hogan, MS, MBA,  
*Chief Business Officer, Somnus Therapeutics*  
 David Ramsay, MBA, *Partner, Care Capital, LLC*  
 Jack W. Britts, *Independent Director*

#### — SCIENTIFIC ADVISORY BOARD —

Charles A. Czeisler, PhD, MD, FRCP  
*Baldino Professor of Sleep Medicine;*  
*Director, Division of Sleep Medicine,*  
*Harvard Medical School;*  
*Chief, Division of Sleep Medicine,*  
*Brigham and Women's Hospital*  
 Daniel J. Buysse, MD  
*Medical Director, Sleep and Chronobiology Program;*  
*Director, Clinical Neuroscience Research Center,*  
*University of Pittsburgh School of Medicine*  
 Gary Cutter, PhD  
*Department of Biostatistics,*  
*University of Alabama at Birmingham*  
 Barbara Harris, PhD  
*PsyPharma Clinical Research, Inc., Phoenix, AZ*  
 Remy Luthringer, PhD  
*FORENAP, Institute for Research in Neurosciences*  
*& Neuropsychiatry, Rouffach, France*  
 Thomas Roth, PhD  
*Chief Division Head, Sleep Disorders and Research*  
*Center, Henry Ford Hospital, Detroit, Mi*  
 James K. Walsh, PhD  
*Sleep Medicine and Research Center, St Luke's*  
*Hospital, Chesterfield, MO*  
 Gary K. Zammit, PhD  
*Sleep Disorders Institute, New York, NY*

#### — CONTACTS—

**General:** Kristy Darcy  
 kdarcy@somnusthera.com  
 908-901-0300 x10

**Clinical:** Anne McCormick  
 amccormick@somnusthera.com  
 908-901-0300 x13

**Media:** Ellen M Martin  
 Kureczka/Martin Associates  
 emm4@pacbell.net  
 510-832-2044

**Somnus Therapeutics, Inc.**  
 135 Route 202/206  
 Bedminster, NJ 07921